



The Honorable Donald J. Trump

President of the United States

The White House

1600 Pennsylvania Avenue NW

Washington, DC 20500

Dear President Trump,

As Co-Chairs of the [Science and Technology Action Committee](#), we write to strongly endorse the recommendations put forward in the final report of the National Security Commission on Emerging Biotechnology. The Science and Technology Action Committee is a group of 25 non-profit, academic, foundation, and corporate leaders working to dramatically strengthen U.S. science and technology.

The United States stands at a critical juncture in the global biotechnology race. The Commission's warning is stark: without bold federal action in the next three years, we risk losing our competitive edge to China. A \$15 billion investment over five years, as recommended in the report, is a strategic imperative. This funding would unlock significant private capital, bolster our innovation ecosystem, and ensure American leadership in biotechnology.

We recognize the alignment of the NSCEB recommendations with addressing the challenges and focusing on the principles you framed in [your insightful letter to the OSTP Director Kratsios](#). We are confident that addressing the NSCEB recommendations would advance your three overarching goals for the U.S. to be: "the unrivaled world leader in critical and emerging technologies," "pursuing truth, reducing administrative burdens, and empowering researchers to achieve groundbreaking discoveries," and ensuring "that scientific progress and technological innovation fuel economic growth and better the lives of all Americans."

We particularly support the creation of a White House National Biotechnology Coordination Office to bring coherence and focus across federal agencies, and the establishment of an Independent Investment Fund to support high-impact biotechnology startups. These actions would accelerate progress and ensure that our science and security priorities are aligned.



We also urge swift action to mobilize the Department of Defense to partner with industry to build critical bio-manufacturing infrastructure and to develop clear rules to prevent U.S. capital from advancing biotechnology efforts in China that could undermine our national security.

This is a moment that demands vision and urgency. We urge your administration to seize this opportunity to act on the Commission's recommendations and secure America's leadership in biotechnology for the decades ahead. As strong supporters of the U.S. science and technology enterprise, we thank you for your leadership and look forward to working with you on these important issues.

Sincerely,

Keith Yamamoto  
Vice Chancellor for  
Science Policy &  
Strategy UCSF

Sudip Parikh  
CEO of the American  
Association for the  
Advancement of  
Science (AAAS)

Mary Woolley  
President & CEO,  
Research!America

Bill Novelli  
Emeritus Professor &  
Founder, Business  
For Impact Center,  
Georgetown's  
McDonough School  
of Business